Full Press Release Details
Microbot Medical Inc. Announces $3.5 Million Registered Direct Offering
Net Proceeds to be Used to Continue Development of Micro-Robotics Technology Platforms
Hingham, MA January 5, 2017 Microbot Medical Inc. (Nasdaq CM: MBOT), a medical device company specializing in the design and development of
transformational micro-robotic medical technologies, announced today that it has entered into a securities purchase agreement with one institutional investor to purchase 700,000 shares of common stock for total gross proceeds of $3.5 million,
before deducting placement agent fees and offering expenses. The offering is expected to close on January 6, 2016, subject to satisfaction of customary closing conditions.
The Company expects to the use the resources from the financing to further develop the Company s transformational micro-robotic technologies that are
designed to treat and diagnose various medical conditions and for general corporate purposes. The Company s initial products are expected to address the unmet medical needs for Cerebrospinal Fluid (CSF) and Gastrointestinal (GI), and are
expected to be submitted the FDA in the near future.
Chardan Capital Markets, LLC acted as the sole placement agent for this transaction.
The shares are being offered by the Company pursuant to an effective shelf registration statement previously filed with and subsequently declared
effective on January 8, 2014 by the Securities and Exchange Commission, that expires on January 8, 2017. The securities are being offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective
registration statement. Copies of the final prospectus supplement and accompanying base prospectus may be obtained, when available, by contacting Chardan Capital Markets, LLC, 150 East 58th Street, 28th Floor, New York, NY 10155, at (646) 465-9028, or the Securities and Exchange Commission s website at http://www.sec.gov.
This press release does not
constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification
under the securities laws of such state. Any offering of the securities under the resale registration statement will only be by means of a prospectus.
About Microbot Medical, Inc.
Microbot was founded in 2010 and became a NASDAQ listed company on November 28, 2016. The Company specializes in transformational micro-robotic medical
technologies leveraging the natural and artificial lumens within the human body. Microbot s current platforms, ViRob and TipCAT, are comprised of two highly advanced micro-robotic technologies, from which the Company is currently developing its
first two product candidates: the Self Cleaning Shunt, or SCS, for the treatment of hydrocephalus and Normal Pressure Hydrocephalus, or NPH; and a self-propelling, semi-disposable endoscope that is being developed initially for use in colonoscopy
procedures. Further information about Microbot Medical is available at http://www.microbotmedical.com.
The ViRob technology is a revolutionary autonomous
crawling micro-robot which can be controlled remotely or within the body. Its miniature dimensions allow it to navigate and crawl in different spaces within the human body, including blood vessels, the digestive tract and the respiratory system. Its
unique structure gives it the ability to move in tight spaces and curved passages as well as the ability to remain within the human body for prolonged time. To learn more about ViRob please visit http://www.microbotmedical.com/technology/virob/.
TipCAT is a transformational self-propelled, flexible, and semi-disposable endoscope providing see & treat capabilities within tubular lumens in
the human body such as the colon, blood vessels, and the urinary tract. Its locomotion mechanism is perfectly suitable to navigate and crawl through natural & artificial tubular lumens, applying the minimal necessary pressure to achieve the
adequate friction required for gentle, fast, and safe advancement within the human body. To learn more about TipCAT visit http://www.microbotmedical.com/technology/tipcat/.
Statements pertaining to future financial
and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or
prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as will, believes, plans,
anticipates, expects and estimates ) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the
development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ
materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the businesses of Microbot Medical Inc. particularly those mentioned in the cautionary
statements found in Microbot Medical Inc. s filings with the Securities and Exchange Commission. Microbot Medical disclaims any intent or obligation to update these forward-looking statements.
Michael Polyviou/Doug